Granisetron hydrochloride (GH) is a potent, selective antagonist of 5-HT3 receptors that is mainly absorbed after oral administration; oral bioavailability is about 60% as a result of first pass hepatic metabolism. The objective of this study was to develop GH-loaded intranasal spanlastic dispersions to produce a more targeted delivery to brain bypassing the liver metabolism and control release of the drug in the brain. GH-loaded spanlastic dispersions were prepared by ethanol injection method using span 60 and tween 60 or tween 80 were explored as edge activators. The prepared eleven dispersions were evaluated for vesicle size, zeta potential, polydispersity index (PI), entrapment efficiency (EE %) and in-vitro drug release studies. The selected dispersions were evaluated for morphology. The best achieved spanlastic dispersions (S4, S9) displayed nanosized spherical vesicles (338.5, 426.6 nm) respectively having a negative zeta potential S4 (-23.1Mv), S9 (-27.5 mV), EE% S4 (22.2%) S9 (24.7%) and optimum specification with drug release about S4 (99.3%), S9 (86.3%) after 6 hrs.
Loading....